The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human phase I study of a selective c-Met inhibitor volitinib (HMP504/AZD6094) in patients with advanced solid tumors.
Hui Kong Gan
No relevant relationships to disclose
Jason Lickliter
No relevant relationships to disclose
Michael Millward
No relevant relationships to disclose
Yi Gu
Employment or Leadership Position - Hutchison MediPharma
Research Funding - Hutchison MediPharma
Other Remuneration - Hutchison MediPharma
Weiguo SU
Employment or Leadership Position - Hutchison MediPharma
Research Funding - Hutchison MediPharma
Other Remuneration - Hutchison MediPharma
Melanie Frigault
Employment or Leadership Position - AstraZeneca
Research Funding - AstraZeneca
Other Remuneration - AstraZeneca
Chuan Qi
Employment or Leadership Position - Hutchison MediPharma
Research Funding - Hutchison MediPharma
Other Remuneration - Hutchison MediPharma
Hua MU
Employment or Leadership Position - Hutchison MediPharma
Research Funding - Hutchison MediPharma
Other Remuneration - Hutchison MediPharma